Transparency notification
pursuant to Article 14 of the Law of May 2, 2007

Leuven (Belgium) - January 3, 2018, 22:00h CEST - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

Summary of the notification

On January 2, 2018, TiGenix received a transparency notification from JPMorgan Chase & Co., following the disposal of voting securities or voting rights in TiGenix on December 28, 2017, after which JPMorgan Chase & Co. (through its subsidiary J.P. Morgan Securities LLC) holds 7,956,525 voting rights in TiGenix (2.90% of the total number of voting rights). As a result the participation of JPMorgan Chase & Co. has fallen below the 3% threshold.

Content of the notification

Date of the notification: January 2, 2018.

Reason of the notification: disposal of voting securities or voting rights; downward crossing of the lowest threshold.

Person subject to the notification requirement: JPMorgan Chase & Co. (with address at c/o CT Corporation, 1209 Orange Street, Wilmington, DE19801, USA), who is a parent undertaking/controlling person.

Date on which the threshold was crossed: December 28, 2017.

Threshold that was crossed: 3%.

Denominator: 274,287,190.

Details of the notification: following the disposal of voting securities or voting rights, the number of voting rights was as follows:
-       JPMorgan Chase & Co. held 0 voting securities; and
-       J.P. Morgan Securities LLC held 7,956,525 voting securities (2.90% of the total number of voting rights).

Chain of controlled undertakings through which the holdings are effectively held: J.P. Morgan Securities LLC is controlled by J.P. Morgan Broker - Dealer Holdings Inc., which is controlled by JPMorgan Chase Holdings LLC, which is controlled by JPMorgan Chase & Co.

Additional information: this position refers to third party shares where rights of use are held.

This press release and the above-mentioned transparency notification can be consulted on our website:

- press release:

- notifications:

For more information:

Claudia Jiménez
Senior Director Investor Relations and Communications
Tel: +34918049264 

About TiGenix

TiGenix NV (Euronext Brussels and Nasdaq: TIG) is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells.

TiGenix lead product, Cx601, has successfully completed a European Phase III clinical trial for the treatment of complex perianal fistulas - a severe, debilitating complication of Crohn's disease. Cx601 has been filed for regulatory approval in Europe and a global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix has entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to develop and commercialize Cx601 for complex perianal fistulas outside the U.S. TiGenix' second adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe sepsis - a major cause of mortality in the developed world. Finally, AlloCSC-01, targeting acute ischemic heart disease, has demonstrated positive results in a Phase I/II trial in acute myocardial infarction (AMI). TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain) and Cambridge, MA (USA). For more information, please visit